Vincent J. Picozzi, MD

Vincent Picozzi, MD, discusses the FDA approval of Optune Pax for locally advanced pancreatic cancer and the criteria for optimal patient selection.

Vincent Picozzi, MD, discusses how data from the phase 3 PANOVA-3 trial are foundational for the evaluation of Optune Pax with other immunotherapies.

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Vincent Picozzi, MD, discusses the addition of TFields to gemcitabine and nab-paclitaxel in locally advanced pancreatic ductal adenocarcinoma.

Vincent J. Picozzi Jr, MD, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.

Vincent J. Picozzi, MD, director, Pancreatic Center of Excellence, Virginia Mason Medical Center, discusses the use of SM-88 in pancreatic cancer.